24 studies found for:    PDGFRA
Show Display Options
Rank Status Study
1 Completed Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors
Conditions: Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach;   Investigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients
Intervention:
2 Recruiting Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
3 Active, not recruiting Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3;   Biological: ramucirumab
4 Active, not recruiting Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene
Condition: D842-related Mutant GIST
Intervention: Drug: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
5 Completed Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
Condition: Solid Tumors
Intervention: Biological: IMC-3G3
6 Terminated A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: imatinib mesylate
7 Recruiting Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent Glioblastoma
Condition: Brain and Nervous System
Interventions: Drug: sorafenib tosylate;   Drug: valproic acid;   Drug: sildenafil citrate
8 Completed Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
Condition: Sarcoma
Interventions: Drug: imatinib mesylate;   Drug: imatinib
9 Completed Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: imatinib mesylate;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
10 Completed A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3;   Drug: liposomal doxorubicin
11 Completed A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
Condition: Cancer
Intervention: Drug: MEDI-575
12 Completed S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
13 Recruiting A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
14 Unknown  Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
Condition: Advanced Biliary Tract Adenocarcinoma
Intervention: Drug: Sunitinib
15 Unknown  Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Pazopanib
16 Recruiting Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
Conditions: Advanced Desmoid Tumor;   Advanced Chondrosarcoma
Intervention: Drug: Imatinib Mesylate
17 Recruiting Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment
Condition: Malignant Solid Neoplasms
Interventions: Drug: Nilotinib (400 mg BID);   Drug: Everolimus (10 mg QD);   Drug: Sorafenib (400 mg BID);   Drug: Lapatinib (1500 mg QD);   Drug: Pazopanib (800 mg QD)
18 Recruiting Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions: Drug: AZD;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
19 Completed A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumours;   Cancer;   Lung Cancer, Non-Small Cell
Interventions: Drug: pazopanib;   Drug: erlotinib;   Drug: pemetrexed
20 Terminated Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: imatinib mesylate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results
Indicates status has not been verified in more than two years